Background: The purpose of this review is to demonstrate the clinical indications, technical developments, and outcome of liver-directed therapies in interventional oncology of non-colorectal liver metastases. Methods: Liver-directed therapies are classified into vascular transarterial techniques such as chemoperfusion (TACP), chemoembolization (TACE), radioembolization (selective internal radiation therapy (SIRT)), and chemosaturation, as well as thermal ablation techniques like microwave ablation (MWA), radiofrequency ablation (RFA), laser-induced thermotherapy (LITT), cryotherapy, and irreversible electroporation (IRE). The authors searched the database PubMed using the following terms: ‘image-guided tumor ablation', ‘thermal ablation therapies', ‘liver metastases of uveal melanoma', ‘neuroendocrine carcinoma', ‘breast cancer', and ‘non-colorectal liver metastases'. Results: Various combinations of the above-mentioned therapy protocols are possible. In neuroendocrine carcinomas, oligonodular liver metastases are treated successfully via thermal ablation like RFA, LITT, or MWA, and diffuse involvement via TACE or SIRT. Although liver involvement in breast cancer is a systemic disease, non-responding nodular metastases can be controlled via RFA or LITT. In ocular or cutaneous melanoma, thermal ablation is rarely considered as an interventional treatment option, as opposed to TACE, SIRT, or chemosaturation. Rarely liver-directed therapies are used in pancreatic cancer, most likely due to problems such as biliary digestive communications after surgery and the risk of infections. Rare indications for thermal ablation are liver metastases of other primary cancers like non-small cell lung, gastric, and ovarian cancer. Conclusion: Interventional oncological techniques play a role in patients with liver-dominant metastases.

Keywords:
Microwave ablation, Non-colorectal liver metastases, Radiofrequency ablation, Laser ablation
1.
Rosenthal DI, Hornicek FJ, Torriani M, Gebhardt MC, Mankin HJ: Osteoid osteoma: percutaneous treatment with radiofrequency energy. Radiology 2003;229:171-175.
2.
Ahmed M, Moussa M, Goldberg SN: Synergy in cancer treatment between liposomal chemotherapeutics and thermal ablation. Chem Phys Lipids 2012;165:424-437.
3.
Spalding AC, Lawrence TS: New and emerging radiosensitizers and radioprotectors. Cancer Invest 2006;24:444-456.
4.
Grieco CA, Simon CJ, Mayo-Smith WW, Di Petrillo TA, Ready NE, Dupuy DE: Percutaneous image-guided thermal ablation and radiation therapy: outcomes of combined treatment for 41 patients with inoperable stage I/II non-small-cell lung cancer. J Vasc Interv Radiol 2006;17:1117-1124.
5.
Ahmed M, Solbiati L, Brace CL, et al: Image-guided tumor ablation: standardization of terminology and reporting criteria - a 10-year update. Radiology 2014;273:241-260.
6.
Dodd GD 3rd, Soulen MC, Kane RA, et al: Minimally invasive treatment of malignant hepatic tumors: at the threshold of a major breakthrough. Radiographics 2000;20:9-27.
7.
Cline HE, Hynynen K, Watkins RD: Focused US system for MR imaging-guided tumor ablation. Radiology 1995;194:731-737.
8.
Vogl TJ, Mack MG, Balzer JO, et al: Liver metastases: neoadjuvant downsizing with transhepatic arterial chemoembolization before laser-induced thermotherapy. Radiology 2003;229:457-464.
9.
Vogl TJ, Straub R, Eichler K, et al: Malignant liver tumors treated with MR imaging-guided laser-induced thermotherapy: experience with complications in 899 patients (2,520 lesions). Radiology 2002;225:367-377.
10.
Hibata T, Limuro Y, Yamamoto Y, et al: Small hepatocellular carcinoma: comparison of radiofrequency ablation and percutaneous microwave coagulation therapy. Radiology 2002;223:331-337.
11.
Bilal Shafi BB, Bilal RH, Evans JC, et al: Percutaneous radiofrequency ablation of liver tumors. http://emedicine.medscape.com/article/1390475 (accessed Jan 7, 2014).
12.
McGahan JP, Dodd GD 3rd: Radiofrequency ablation of the liver. AJR Am J Roentgenol 2001;176:13-16.
13.
Goldberg SN, Gazelle GS, Dawson SL, Rittman WJ, Mueller PR, Rosenthal DI: Tissue ablation with radiofrequency: effect of probe size, gauge, duration, and temperature on lesion volume. Acad Radiol 1995;2:399-404.
14.
Goldberg SN, Gazelle GS, Solbiati L, Rittman WJ, Mueller PR: Radiofrequency tissue ablation: increased lesion. Acad Radiol 1996;3:636-644.
15.
Vogl TJ, Naguib NN, Zangos S, Eichler K, Hedayati A, Nour-Eldin NE: Liver metastases of neuroendocrine carcinomas: interventional treatment via transarterial embolization, chemoembolization and thermal ablation. Eur J Radiol 2009;72:517-528.
16.
Vogl TJ, Farshid P, Naguib NN, Zangos S: Thermal ablation therapies in patients with breast cancer liver metastases: a review. Eur Radiol 2013;23:797-804.
17.
Vogl TJ, Kreutzträger M, Gruber-Rouh T, Eichler K, Nour-Eldin NE, Zangos S, Naguib NN: Neoadjuvant TACE before laser-induced thermotherapy (LITT) in the treatment of non-colorectal non-breast cancer liver metastases: feasibility and survival rates. Eur J Radiol 2014;83:1804-1810.
18.
Vogl TJ, Freier V, Nour-Eldin NE, Eichler K, Zangos S, Naguib NN: Magnetic resonance-guided laser-induced interstitial thermotherapy of breast cancer liver metastases and other non-colorectal cancer liver metastases: an analysis of prognostic factors for long-term survival and progression-free survival. Invest Radiol 2013;48:406-412.
19.
Vogl TJ, Zangos S, Scholtz JE, Schmitt F, Paetzold S, Trojan J, Orsi F, Lotz G, Ferrucci P: Chemosaturation with percutaneous hepatic perfusions of melphalan for hepatic metastases: experience from two European centers. Rofo 2014;186:937-944.
20.
Eichler K, Zangos S, Gruber-Rouh T, Vogl TJ, Mack MG: MR-guided laser-induced thermotherapy (LITT) in patients with liver metastases of uveal melanoma. J Eur Acad Dermatol Venerol 2014;28:1756-1760.
21.
Park JB, Kim YH, Kim J, Chang HM, Kim TW, Kim SC, Kim PN, Han DJ: Radiofrequency ablation of liver metastasis in patients with locally controlled pancreatic ductal adenocarcinoma. J Vasc Interv Radiol 2012;23:635-641.
22.
Kyildiz HY, Mitchell J, Milas M, Siperstein A, Berber E: Laparoscopic radiofrequency thermal ablation of neuroendocrine hepatic metastases: long-term follow-up. Surgery 2010;148:1288-1293.
23.
Mazzaglia PJ, Berber E, Milas M, Siperstein AE: Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival. Surgery 2007;142:10-19.
24.
De Baere T, Elias D, Dromain C, Din MG, Kuoch V, Ducreux M, Boige V, Lassau N, Marteau V, Lasser P, Roche A: Radiofrequency ablation of 100 hepatic metastases with a mean follow-up of more than 1 year. AJR Am J Roentgenol 2000;175:1619-1625.
25.
Perälä J, Klemola R, Kallio R, Li C, Vihriälä I, Salmela PI, Tervonen O, Sequeiros RB: MRI-guided laser ablation of neuroendocrine tumor hepatic metastases. Acta Radiol Short Rep 2014;3:2047981613499753.
26.
Vogl TJ, Zangos S, Heller M, Hammerstingl R, Böcher E, Jacob U, Bauer RW: Transarterial chemoperfusion with gemcitabine and mitomycin C in pancreatic carcinoma: results in locally recurrent tumors and advanced tumor stages (Article in German). Rofo 2007;179:1181-1188.
27.
Vogl TJ, Heller M, Zangos S, Schwarz W, Eichler K, Mack MG, Berger D, Balzer JO: Transarterial chemoperfusion of inoperable pancreas carcinoma and local recurrence (Article in German). Rofo 2003;175:695-704.
28.
Akahori T, Sho M, Tanaka T, Nishiofuku H, Kinoshita S, Nagai M, Kichikawas K, Nakajima Y: Significant efficacy of new transcatheter arterial chemoembolization technique for hepatic metastases of pancreatic neuroendocrine tumors. Anticancer Res 2013;33:3355-3358.
29.
Azizi A, Naguib NN, Mbalisike E, Farshid P, Emami AH, Vogl TJ: Liver metastases of pancreatic cancer: role of repetitive transarterial chemoembolization (TACE) on tumor response and survival rate. Pancreas 2011;40:1271-1275.
30.
Jarzabek M, Jargietto T, Wolski A, Poluha P, Szczerbo-Trojanowska M: Drug-eluting microspheres transarterial chemoembolization (DEM TACE) in patients with liver metastases. Pilot study. Pol J Radiol 2001;76:26-32.
31.
De Baere T, Deschamps F, Teritheau C, Rao P, Conengrapht K, Schlumberger M, Leboulleux S, Baudin E, Hechelhammer L: Transarterial chemoembolization of liver metastases from well differentiated gastroenteropancreatic endocrine tumors with doxorubicin-eluting beads: preliminary results. J Vasc Interv Radiol 2008;19:855-861.
32.
Kress O, Wagner HJ, Wied M, Klose KJ, Arnold R, Alfke H: Transarterial chemoembolization of advanced liver metastases of neuroendocrine tumors - a retrospective single-center analysis. Digestion 2003;68:94-101.
33.
Schuster R, Lindner M, Wacker F, Krössin M, Bechrakis N, Foerster MH, Thiel E, Keilholz U, Schmittel A: Transarterial chemoembolization of liver metastases from uveal melanoma after failure of systemic therapy: toxicity and outcome. Melanoma Res 2010;20:191-196.
34.
Huppert PE, Fierlbeck G, Pereira P, Schanz S, Duda SH, Wietholtz H, Rozeik C, Claussen CD: Transarterial chemoembolization of liver metastases in patients with uveal melanoma. Eur J Radiol 2010;74:e38-44.
35.
Fiorentini G, Aliberti C, Del Conte A, Tilli M, Rossi S, Ballardini P, Turrisi G, Benea G: Intra-arterial hepatic chemoembolization (TACE) of liver metastases from ocular melanoma with slow-release irinotecan-eluting beads. Early results of a phase II clinical study. In Vivo 2009;23:131-137.
36.
Vogl TJ, Eichler K, Zangos S, Herzog C, Hammerstingl R, Balzer J, Gholami A: Preliminary experience with transarterial chemoembolization (TACE) in liver metastases of uveal malignant melanoma: local tumor control and survival. J Cancer Res Clin Oncol 2007;133:177-184.
37.
Patel K, Sullivan K, Berd D, Mastrangelo MJ, Shields CL, Shields JA, Sato T: Chemoembolization of the hepatic artery with BCNU for metastatic uveal melanoma: results of a phase II study. Melanoma Res 2005;15:297-304.
38.
Peker A, Cicek O, Soydal Ç, Küçük NÖ, Bilgiç S: Radioembolization with yttrium-90 resin microspheres for neuroendocrine tumor liver metastases. Diagn Interv Radiol 2015;21:54-59.
39.
Devcic Z, Rosenberg J, Braat AJ, Techasith T, Banerjee A, Sze DY, Lam MG: The efficacy of hepatic 90Y resin radioembolization for metastatic neuroendocrine tumors: a meta-analysis. Nucl Med 2014;55:1404-1410.
40.
Michl M, Haug AR, Jakobs TF, Paprottka P, Hoffmann RT, Bartenstein P, Boeck S, Haas M, Laubender RP, Heinemann V: Radioembolization with Yttrium-90 microspheres (SIRT) in pancreatic cancer patients with liver metastases: efficacy, safety and prognostic factors. Oncology 2014;86:24-32.
41.
Paprottka PM, Hoffmann RT, Haug A, Sommer WH, Raessler F, Trumm CG, Schmidt GP, Ashoori N, Reiser MF, Jakobs TF: Radioembolization of symptomatic, unresectable neuroendocrine hepatic metastases using yttrium-90 microspheres. Cardiovasc Intervent Radiol 2011;35:334-342.
© 2015 S. Karger GmbH, Freiburg
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.